Insilico expands Tenacia CNS alliance in $94.75M AI deal

Version 1

Insilico Medicine and Tenacia Biotechnology said on March 26, 2026 that they’re expanding their central nervous system drug discovery collaboration, adding a second AI-designed program with potential deal value of up to $94.75 million. The companies said the original collaboration, launched in March 2025, focused on small-molecule inhibitors designed for strong blood-brain barrier permeability, and that the new agreement will push an additional neurological candidate through preclinical candidate stage. Insilico said it would be eligible for near-term and milestone payments from Tenacia. Tenacia, founded in 2022 with backing from Bain Capital Life Sciences, is focused on treatments for CNS disorders. (prnewswire.com)

Why it matters: While this is a human biopharma deal, it’s another sign that AI-enabled drug discovery platforms are moving from pilot work into repeat business, especially in hard-to-treat neurology, where blood-brain barrier challenges have long slowed R&D. For veterinary professionals, that matters less because of any immediate clinical impact and more because these platform models increasingly spill into adjacent animal health applications; Insilico itself says it is extending Pharma.AI into veterinary medicine as part of its broader business. The expansion also comes just days before news of Insilico’s separate multibillion-dollar AI discovery pact with Eli Lilly, underscoring how quickly commercial interest in AI-led discovery is scaling. (prnewswire.com)

What to watch: Watch for target disclosure, preclinical candidate timing, and whether Insilico’s growing CNS deal flow translates into animal health partnerships or translational neuro programs relevant to veterinary medicine. (prnewswire.com)